Gene Therapy for Follicular Lymphoma: Emerging Strategies and CAR-T Advances

Follicular lymphoma (FL) is an indolent B-cell non-Hodgkin lymphoma defined by the t(14;18)(q32;q21) translocation, creating the BCL2-IGH fusion gene that drives BCL2 overexpression and apoptosis blockade. Gene therapy aims to reverse this driver or harness immunity against it.

Strategies Under Investigation

1. Targeting t(14;18) / BCL2

• siRNA/shRNA against BCL2: Restores apoptotic sensitivity; shows preclinical synergy with venetoclax.
• CRISPR/Cas9 disruption of BCL2-IGH junction: Permanent oncogene inactivation — delivery to malignant B cells remains challenging.
• BCL2 antisense oligonucleotides (e.g., oblimersen): Failed in Phase III; newer LNP-formulated siRNAs in early trials.

2. CAR T-Cell Therapy (Autologous)

• Target: CD19 (axicabtagene ciloleucel, tisagenlecleucel, lisocabtagene maraleucel) or CD20 (investigational).
• Efficacy: ZUMA-5 (axi-cel): ORR 94%, CR 75% in relapsed/refractory FL (median 3 prior lines). ELARA (tisa-cel): ORR 92%, CR 68%.
• Durability: Median duration of response ~3–4 years; plateau suggests cure fraction.
• Toxicity: CRS (Grade ≥3 ~5–10%), ICANS (~10%), prolonged cytopenias, hypogammaglobulinemia.

3. Tumor Microenvironment (TME) Reprogramming

• Cytokine-armed CAR-T: IL-12, IL-18, or IL-7/CCL19 secretion → recruit/activate endogenous T/NK cells, remodel fibrotic TME.
• In vivo CAR-T generation: mRNA-LNP or viral vectors injectable systemically — avoids manufacturing delay.
• Checkpoint modulation: PD-1 knockout in CAR-T (CRISPR) or combo with anti-PD-1 — counteracts TME exhaustion.

4. Bispecific Antibodies (Bridge to Gene Therapy)

Mosunetuzumab (CD20×CD3), epcoritamab (CD20×CD3), glofitamab (CD20×CD3) — fixed-duration, off-the-shelf, high CR rates (60–80%). Not gene therapy but same target space.

Challenges and Future Directions

• Antigen escape (CD19/CD20 loss) — dual-target CARs (CD19×CD20, BCMA×CD19).
• Manufacturing failure in heavily pre-treated patients (low T-cell fitness).
• Cost/access: ~$400–500K per infusion; equity concerns.
• Long-term safety: insertional mutagenesis (theoretical), secondary T-cell malignancies (rare, under surveillance).

Gene and cellular therapies are redefining follicular lymphoma from a chronically relapsing disease to a potentially curable one — with CAR-T leading the clinical charge today.